Addex Therapeutics Accounts Payable

Addex Therapeutics (ADXN) currently reports a accounts payable of $630K as of March 2026. That compares with $290K in the prior-year period — up 121.2% year over year. Use the charts on this page to explore Addex Therapeutics's accounts payable history and peer comparisons.

Addex Therapeutics's accounts payable increased from $290K to $630K — a 121.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Addex Therapeutics reported $630K in accounts payable as of March 2026. That compares with $290K in the prior-year period — up 121.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $630K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Addex Therapeutics, and consider following ADXN for alerts when major investors trade the stock.

Addex Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $630K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADXN with unrelated industries.